目的:探讨术前CRP/ALB、P-CRP与宫颈癌预后的预测价值。方法:选取临沂市肿瘤医院自2015年1月至2019年1月收治的265例行经腹广泛性子宫切除的FIGO 2009 IB1-IIA2期宫颈癌患者的临床病理资料及随访资料。检测术前:CRP与ALB、血小板,计算CR...目的:探讨术前CRP/ALB、P-CRP与宫颈癌预后的预测价值。方法:选取临沂市肿瘤医院自2015年1月至2019年1月收治的265例行经腹广泛性子宫切除的FIGO 2009 IB1-IIA2期宫颈癌患者的临床病理资料及随访资料。检测术前:CRP与ALB、血小板,计算CRP/ALB、P-CRP值,绘制受试者工作特征(ROC)曲线得到上述指标的最佳cut-off值并根据cut-off值分为相应指标的高水平组、低水平组。比较相应指标的高水平组、低水平组临床病理资料,采用Kaplan-Meier进行相应生存分析。采用COX多因素分析宫颈癌患者预后的相关影响因素。结果:随访最终截止时间为2024年1月,根据纳入患者随访期间生存、死亡情况将患者分为生存组(223例)、死亡组(42例)。ROC结果显示:CRP/ALB预测IB1-IIA2期宫颈癌生存的曲线下面积(AUC)为:0.866 (95%CI: 0.828~0.944, P χ2 = 23.302, P χ2 =12.305, P χ2 =28.237, P χ2 = 101.439, P χ2 = 8.348, P= 0.004;χ2 =7.225, P = 0.007;χ2 = 9.887, P = 0.002);高P-CRP组共死亡28例(66.67%),低P-CRP组死亡14例(33.33%),两组死亡率差异有统计学意义(χ2 = 27.411, P χ2 = 125.945, P χ2 = 26.830, P 0.359、P-CRP > 3.386是IB1-IIA2期宫颈癌生存的独立危险因子,且CRP/ALB、P-CRP对宫颈癌生存率具有一定的预测价值。术前检测CRP、白蛋白、血小板水平并及时干预对提高生存率具有一定意义。Objective: To investigate the predictive value of preoperative CRP/ALB and P-CRP in the prognosis of cervical cancer. Methods: The clinicopathological data and follow-up data of 265 patients with FIGO 2009 IB1-IIA2 cervical cancer who underwent radical abdominal hysterectomy admitted to Linyi Cancer Hospital from January 2015 to January 2019 were enrolled. Preoperatively, CRP, ALB and platelets were detected, CRP/ALB and P-CRP values were calculated, and the receiver operating characteristic (ROC) curve was drawn to obtain the best cut-off values of the above indexes, and the cut-off values were divided into high-level group and low-level group of corresponding indexes. The clinicopathological data of the high-level group and the low-level group were compared, and Kaplan-Meier was used for survival analysis. COX univariate and multivariate analysis were used to analyze the prognosis of cervical cancer patients. Results: The final cut-off time of follow-up was January 2024, and the patients were divided into survival group (223 cases) and death group (42 cases) according to their survival and death during the follow-up period. The ROC results showed that the area under the curve (AUC) of CRP/ALB for predicting mortality from stage IB1-IIA2 cervical cancer was 0.866 (95%CI: 0.828~0.944, P χ2 = 23.302, P χ2 =12.305, P χ2 = 28.237, P χ2 = 101.439, P χ2 = 8.348, P = 0.004;χ2 = 7.225, P = 0.007;χ2 = 9.887, P = 0.002);a total of 28 cases (66.67%) died in the high P-CRP group and 14 cases (33.33%) died in the low P-CRP group, and the difference in mortality between the two groups was statistically significant (χ2 = 27.411, P χ2 = 125.945, P χ2 = 26.830, P 0.359 and P-CRP > 3.386 are independent risk factors for the survival of stage IB1-IIA2 cervical cancer, and CRP/ALB and P-CRP have certain predictive value for the survival rate of cervical cancer. Preoperative detection of CRP, albumin, and platelet levels and timely intervention are of certain significance to improve the survival rate.展开更多
近日,为满足医疗保健行业对先进材料日益增长的需求,阿科玛和ALBIS宣布建立战略合作伙伴关系,分销阿科玛的高性能医用级聚合物。ALBIS将分销阿科玛的一系列医用级材料,包括Pebax^(®) MED热塑性弹性体、Rilsan^(®) MED聚酰胺11...近日,为满足医疗保健行业对先进材料日益增长的需求,阿科玛和ALBIS宣布建立战略合作伙伴关系,分销阿科玛的高性能医用级聚合物。ALBIS将分销阿科玛的一系列医用级材料,包括Pebax^(®) MED热塑性弹性体、Rilsan^(®) MED聚酰胺11、Rilsamid^(®) MED聚酰胺12、Rilsan^(®) MED Clear透明聚酰胺和Kynar^(®) MED PVDF。展开更多
文摘目的:探讨术前CRP/ALB、P-CRP与宫颈癌预后的预测价值。方法:选取临沂市肿瘤医院自2015年1月至2019年1月收治的265例行经腹广泛性子宫切除的FIGO 2009 IB1-IIA2期宫颈癌患者的临床病理资料及随访资料。检测术前:CRP与ALB、血小板,计算CRP/ALB、P-CRP值,绘制受试者工作特征(ROC)曲线得到上述指标的最佳cut-off值并根据cut-off值分为相应指标的高水平组、低水平组。比较相应指标的高水平组、低水平组临床病理资料,采用Kaplan-Meier进行相应生存分析。采用COX多因素分析宫颈癌患者预后的相关影响因素。结果:随访最终截止时间为2024年1月,根据纳入患者随访期间生存、死亡情况将患者分为生存组(223例)、死亡组(42例)。ROC结果显示:CRP/ALB预测IB1-IIA2期宫颈癌生存的曲线下面积(AUC)为:0.866 (95%CI: 0.828~0.944, P χ2 = 23.302, P χ2 =12.305, P χ2 =28.237, P χ2 = 101.439, P χ2 = 8.348, P= 0.004;χ2 =7.225, P = 0.007;χ2 = 9.887, P = 0.002);高P-CRP组共死亡28例(66.67%),低P-CRP组死亡14例(33.33%),两组死亡率差异有统计学意义(χ2 = 27.411, P χ2 = 125.945, P χ2 = 26.830, P 0.359、P-CRP > 3.386是IB1-IIA2期宫颈癌生存的独立危险因子,且CRP/ALB、P-CRP对宫颈癌生存率具有一定的预测价值。术前检测CRP、白蛋白、血小板水平并及时干预对提高生存率具有一定意义。Objective: To investigate the predictive value of preoperative CRP/ALB and P-CRP in the prognosis of cervical cancer. Methods: The clinicopathological data and follow-up data of 265 patients with FIGO 2009 IB1-IIA2 cervical cancer who underwent radical abdominal hysterectomy admitted to Linyi Cancer Hospital from January 2015 to January 2019 were enrolled. Preoperatively, CRP, ALB and platelets were detected, CRP/ALB and P-CRP values were calculated, and the receiver operating characteristic (ROC) curve was drawn to obtain the best cut-off values of the above indexes, and the cut-off values were divided into high-level group and low-level group of corresponding indexes. The clinicopathological data of the high-level group and the low-level group were compared, and Kaplan-Meier was used for survival analysis. COX univariate and multivariate analysis were used to analyze the prognosis of cervical cancer patients. Results: The final cut-off time of follow-up was January 2024, and the patients were divided into survival group (223 cases) and death group (42 cases) according to their survival and death during the follow-up period. The ROC results showed that the area under the curve (AUC) of CRP/ALB for predicting mortality from stage IB1-IIA2 cervical cancer was 0.866 (95%CI: 0.828~0.944, P χ2 = 23.302, P χ2 =12.305, P χ2 = 28.237, P χ2 = 101.439, P χ2 = 8.348, P = 0.004;χ2 = 7.225, P = 0.007;χ2 = 9.887, P = 0.002);a total of 28 cases (66.67%) died in the high P-CRP group and 14 cases (33.33%) died in the low P-CRP group, and the difference in mortality between the two groups was statistically significant (χ2 = 27.411, P χ2 = 125.945, P χ2 = 26.830, P 0.359 and P-CRP > 3.386 are independent risk factors for the survival of stage IB1-IIA2 cervical cancer, and CRP/ALB and P-CRP have certain predictive value for the survival rate of cervical cancer. Preoperative detection of CRP, albumin, and platelet levels and timely intervention are of certain significance to improve the survival rate.
文摘近日,为满足医疗保健行业对先进材料日益增长的需求,阿科玛和ALBIS宣布建立战略合作伙伴关系,分销阿科玛的高性能医用级聚合物。ALBIS将分销阿科玛的一系列医用级材料,包括Pebax^(®) MED热塑性弹性体、Rilsan^(®) MED聚酰胺11、Rilsamid^(®) MED聚酰胺12、Rilsan^(®) MED Clear透明聚酰胺和Kynar^(®) MED PVDF。
